BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219

Differential expression analysis for sequence count data

Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.

Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668

Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction: Results of the Survival and Ventricular Enlargement Trial

Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911

Causal analysis approaches in Ingenuity Pathway Analysis

Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study

Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262

Role of the gut microbiota in nutrition and health

Valdes, A. M., Walter, J., Segal, E., & Spector, T. D. (2018) · BMJ · doi:10.1136/bmj.k2179 · Cited by 2,375

Microglia in Alzheimer’s disease

Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935

Cardiac fibrosis

Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Gilan, O., Rioja, I., Knezevic, K., Bell, M. J., Yeung, M. M., Harker, N., Lam, E. Y. N., Chung, C., Bamborough, P., Petretich, M., et al. (2020) · Science · doi:10.1126/science.aaz8455 · Cited by 453

Bromodomains: a new target class for drug development

Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 450

Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity

Richards, D. J., Li, Y., Kerr, C. M., Yao, J., Beeson, G. C., Coyle, R. C., Chen, X., Jia, J., Damon, B., Wilson, R., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0539-4 · Cited by 439

Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials

Shi, Y., Zhang, H., Huang, S., Yin, L., Wang, F., Luo, P., & Huang, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01055-2 · Cited by 377

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Liu, M., Abad, B. L. D. J., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.021 · Cited by 370

The BET family in immunity and disease

Wang, N., Wu, R., Tang, D., & Kang, R. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00384-4 · Cited by 295

Targeting Age-Related Pathways in Heart Failure

Li, H., Hastings, M. H., Rhee, J., Trager, L. E., Roh, J. D., & Rosenzweig, A. (2020) · Circulation Research · doi:10.1161/circresaha.119.315889 · Cited by 276

A transcriptional switch governs fibroblast activation in heart disease

Alexanian, M., Przytycki, P. F., Micheletti, R., Padmanabhan, A., Ye, L., Travers, J. G., Gonzalez-Teran, B., Silva, A. C., Duan, Q., Ranade, S. S., et al. (2021) · Nature · doi:10.1038/s41586-021-03674-1 · Cited by 238

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

Mills, R. J., Humphrey, S. J., Fortuna, P. R. J., Lor, M., Foster, S. R., Quaife-Ryan, G. A., Johnston, R. L., Dumenil, T. D., Bishop, C., Rudraraju, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.026 · Cited by 229

Oligogenic inheritance of a human heart disease involving a genetic modifier

Gifford, C. A., Ranade, S. S., Samarakoon, R., Salunga, H. T., de Soysa, Y., Huang, Y., Zhou, P., Elfenbein, A., Wyman, S. K., Bui, Y. K., et al. (2019) · Science · doi:10.1126/science.aat5056 · Cited by 223

DoubletDecon: Deconvoluting Doublets from Single-Cell RNA-Sequencing Data

DePasquale, E. A. K., Schnell, D. J., Van Camp, P.-J., Valiente-Alandí, Í., Blaxall, B. C., Grimes, H. L., Singh, H., & Salomonis, N. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.082 · Cited by 207

Cardiac fibrosis: potential therapeutic targets

Park, S., Nguyen, N. B., Pezhouman, A., & Ardehali, R. (2019) · Translational research · doi:10.1016/j.trsl.2019.03.001 · Cited by 194

Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation

Stratton, M. S., Bagchi, R. A., Felisbino, M. B., Hirsch, R. A., Smith, H. E., Riching, A. S., Enyart, B. Y., Koch, K. A., Cavasin, M. A., Alexanian, M., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315125 · Cited by 179

Therapeutic targets for cardiac fibrosis: from old school to next-gen

Travers, J. G., Tharp, C. A., Rubino, M., & McKinsey, T. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148554 · Cited by 179

Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension

van der Feen, D. E., Kurakula, K., Tremblay, È., Boucherat, O., Bossers, G. P. L., Szulcek, R., Bourgeois, A., Lampron, M.-C., Habbout, K., Martineau, S., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201812-2275oc · Cited by 157

BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs

Borck, P. C., Guo, L., & Plutzky, J. (2020) · Circulation Research · doi:10.1161/circresaha.120.315929 · Cited by 155

Epigenetics in Cardiac Hypertrophy and Heart Failure

Liu, C., & Tang, W. H. W. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.011 · Cited by 150

Autophagy enhanced by curcumin ameliorates inflammation in atherogenesis via the TFEB–P300–BRD4 axis

Li, X., Zhu, R., Jiang, H., Yin, Q., Gu, J., Chen, J., Ji, X., Wu, X., Fu, H., Wang, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.014 · Cited by 145

Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies

Ravassa, S., López, B., Treibel, T. A., José, G. S., Losada-Fuentenebro, B., Tapia, L., Bayés‐Genís, A., Díez, J., & González, A. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101194 · Cited by 139

Chromatin remodelling drives immune cell–fibroblast communication in heart failure

Alexanian, M., Padmanabhan, A., Nishino, T., Travers, J. G., Ye, L., Pelonero, A., Lee, C. Y., Sadagopan, N., Huang, Y., Auclair, K., et al. (2024) · Nature · doi:10.1038/s41586-024-08085-6 · Cited by 140

BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses

Dey, A., Yang, W., Gégonne, A., Nishiyama, A., Pan, R., Yagi, R., Grinberg, A., Finkelman, F. D., Pfeifer, K. E., Zhu, J., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100293 · Cited by 128

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

Zhang, Q.-J., Tran, T. A. T., Wang, M., Ranek, M. J., Kokkonen-Simon, K. M., Gao, J., Luo, X., Tan, W. H., Kyrychenko, V., Liao, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07173-2 · Cited by 126

Epigenetics in Cardiac Fibrosis

Felisbino, M. B., & McKinsey, T. A. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.05.003 · Cited by 124

Single-cell transcriptomics for the assessment of cardiac disease

Miranda, A. M. A., Janbandhu, V., Maatz, H., Kanemaru, K., Cranley, J., Teichmann, S. A., Hübner, N., Schneider, M. D., Harvey, R. P., & Noseda, M. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00805-7 · Cited by 117

Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy

Chelladurai, P., Boucherat, O., Stenmark, K. R., Kracht, M., Seeger, W., Bauer, U., Bonnet, S., & Pullamsetti, S. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14932 · Cited by 117

Signaling Mechanisms of Myofibroblastic Activation: Outside-in and Inside-Out

Zent, J. M., & Guo, L. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493217 · Cited by 117

Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors

Bechter, O. E., & Schöffski, P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107479 · Cited by 117

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases

Kulikowski, E., Rakai, B. D., & Wong, N. C. W. (2020) · Medicinal Research Reviews · doi:10.1002/med.21730 · Cited by 109

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

Liu, Z., Chen, H., Wang, P., Li, Y., Wold, E. A., Leonard, P. G., Joseph, S., Brasier, A. R., Tian, B., & Zhou, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00035 · Cited by 106

Systemic Aging Fuels Heart Failure: Molecular Mechanisms and Therapeutic Avenues

Fang, Z., Raza, U., Song, J., Lu, J., Yao, S., Liu, X., Zhang, W., & Li, S. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14947 · Cited by 117

Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells

Das, S., Senapati, P., Chen, Z., Reddy, M. A., Ganguly, R., Lanting, L. L., Mandi, V., Bansal, A., Leung, A., Zhang, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01629-7 · Cited by 105

Role of the Epigenome in Heart Failure

Papait, R., Serio, S., & Condorelli, G. (2020) · Physiological Reviews · doi:10.1152/physrev.00037.2019 · Cited by 107

p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization

Peng, J., Li, J., Huang, J. L., Xu, P., Huang, H., Liu, Y., Liang, Y., Yang, Y., Zhou, B., Jiang, H., et al. (2019) · Theranostics · doi:10.7150/thno.30707 · Cited by 106

BRD4 inhibition by JQ1 prevents high-fat diet-induced diabetic cardiomyopathy by activating PINK1/Parkin-mediated mitophagy in vivo

Mu, J., Zhang, D., Tian, Y., Xie, Z., & Zou, M. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.09.003 · Cited by 102

Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-β-induced endothelial-mesenchymal transition and cardiac fibrosis

Song, S., Liu, L., Yu, Y., Zhang, R., Li, Y., Cao, W., Xiao, Y., Fang, G., Li, Z., Wang, X., et al. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.12.002 · Cited by 102

Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases

Morgado‐Pascual, J. L., Rayego‐Mateos, S., Tejedor-Santamaria, L., Suárez-Álvarez, B., & Ruiz‐Ortega, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01315 · Cited by 103

Epigenetic Reader BRD4 (Bromodomain-Containing Protein 4) Governs Nucleus-Encoded Mitochondrial Transcriptome to Regulate Cardiac Function

Kim, S. Y., Zhang, X., Schiattarella, G. G., Altamirano, F. J., Ramos, T. A. R., French, K. M., Jiang, N., Szweda, P. A., Evers, B. M., May, H. I., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047239 · Cited by 90

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

the BETonMACE Investigators, Nicholls, S. J., Schwartz, G. G., Buhr, K. A., Ginsberg, H. N., Johansson, J. O., Kalantar‐Zadeh, K., Kulikowski, E., Toth, P. P., Wong, N. C. W., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01199-x · Cited by 86

Antihypertrophic Memory After Regression of Exercise-Induced Physiological Myocardial Hypertrophy Is Mediated by the Long Noncoding RNA Mhrt779

Lin, H., Zhu, Y., Zheng, C., Hu, D., Ma, S., Chen, L., Wang, Q., Chen, Z., Xie, J., Yan, Y., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.047000 · Cited by 88

DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure

Pepin, M. E., Drakos, S. G., Ha, C., Tristani‐Firouzi, M., Selzman, C. H., Fang, J. C., Wende, A. R., & Wever‐Pinzon, O. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00016.2019 · Cited by 86

BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C–deficient mice

Auguste, G., Rouhi, L., Matkovich, S. J., Coarfa, C., Robertson, M. J., Czernuszewicz, G., Gurha, P., & Marian, A. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135922 · Cited by 77

Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development

McKinsey, T. A., Foo, R., Anene-Nzelu, C. G., Travers, J. G., Vagnozzi, R. J., Weber, N., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac142 · Cited by 84

Epigenomes in Cardiovascular Disease

Rosa‐Garrido, M., Chapski, D. J., & Vondriska, T. M. (2018) · Circulation Research · doi:10.1161/circresaha.118.311597 · Cited by 73

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

Liu, Z., Li, Y., Chen, H., Lai, H., Wang, P., Wu, S., Wold, E. A., Leonard, P. G., Joseph, S., Hu, H., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01851 · Cited by 70

Platelet and Erythrocyte Membranes Coassembled Biomimetic Nanoparticles for Heart Failure Treatment

Li, Y., Yu, J., Chen, C., Chen, W., Lin, R., Wang, Y., Cui, W., Meng, J., Du, J., & Wang, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c04814 · Cited by 69

BRD4 inhibition regulates MAPK, NF‐κB signals, and autophagy to suppress MMP‐13 expression in diabetic intervertebral disc degeneration

Wang, J., Hu, J., Chen, X., Huang, C., Lin, J., Shao, Z., Gu, M., Wu, Y., Tian, N., Gao, W., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900703r · Cited by 68

Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins

Chen, D., Lu, T., Yan, Z., Lu, W., Zhou, F., Lyu, X., Xu, B., Jiang, H., Chen, K., Luo, C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111633 · Cited by 67

cellHarmony: cell-level matching and holistic comparison of single-cell transcriptomes

DePasquale, E. A. K., Schnell, D., Dexheimer, P., Ferchen, K., Hay, S., Chetal, K., Valiente-Alandí, Í., Blaxall, B. C., Grimes, H. L., & Salomonis, N. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz789 · Cited by 67

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65

Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances

Ahmed, S. T., Cerosaletti, K. M., James, E. A., Long, S. A., Mannering, S. I., Speake, C., Nakayama, M., Tree, T. I. M., Roep, B. O., Herold, K. C., et al. (2019) · Diabetes · doi:10.2337/db19-0119 · Cited by 66

Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic Cardiomyopathy

Knight, W. E., Cao, Y., Lin, Y.-H., Chi, C., Bai, B., Sparagna, G. C., Zhao, Y., Du, Y., Londono, P., Reisz, J. A., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.01.018 · Cited by 68

BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes

Padmanabhan, A., Alexanian, M., Linares-Saldana, R., González-Terán, B., Andreoletti, G., Huang, Y., Connolly, A. J., Kim, W., Hsu, A., Duan, Q., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047753 · Cited by 60

BRD4 inhibition for the treatment of pathological organ fibrosis

Stratton, M. S., Haldar, S. M., & McKinsey, T. A. (2017) · F1000Research · doi:10.12688/f1000research.11339.1 · Cited by 58

Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases

Klein, K. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000744 · Cited by 58

Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases

Yu, Y., Su, X., Qin, Q., Hou, Y., Zhang, X., Zhang, H., Jia, M., & Chen, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105009 · Cited by 61

Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies

Hamdani, N., Costantino, S., Mügge, A., Lebeche, D., Tschöpe, C., Thum, T., & Paneni, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab197 · Cited by 56

Epigenetics-based therapeutics for myocardial fibrosis

Li, X., Yang, Y., Chen, S., Zhou, J., Li, J., & Cheng, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119186 · Cited by 55

Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling

Hsu, A., Duan, Q., McMahon, S., Huang, Y., Wood, S. A. B., Gray, N. S., Wang, B., Bruneau, B. G., & Haldar, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133753 · Cited by 54

Myocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact

Lunde, I. G., Rypdal, K. B., Linthout, S. V., Díez, J., & González, A. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.08.008 · Cited by 61

Conserved Epigenetic Regulatory Logic Infers Genes Governing Cell Identity

Shim, W. J., Sinniah, E., Xu, J., Vitrinel, B., Alexanian, M., Andreoletti, G., Shen, S., Sun, Y., Balderson, B., Boix, C. A., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.001 · Cited by 50

Elevated H3K27ac in aged skeletal muscle leads to increase in extracellular matrix and fibrogenic conversion of muscle satellite cells

Zhou, J., So, K. K. H., Li, Y., Li, Y., Yuan, J., Ding, Y., Chen, F., Huang, Y., Liu, J., Lee, W., et al. (2019) · Aging Cell · doi:10.1111/acel.12996 · Cited by 52

Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction

Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 52

Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling

Brasier, A. R., & Zhou, J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.002 · Cited by 48

TEA domain transcription factor 1 (TEAD1) induces cardiac fibroblasts cells remodeling through BRD4/Wnt4 pathway

Song, S., Zhang, X., Huang, Z., Zhao, Y., Lu, S., Zeng, L., Cai, F., Wang, T., Pei, Z., Weng, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01732-w · Cited by 47

Epigenetics and vascular diseases

Stratton, M. S., Farina, F. M., & Elia, L. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.06.010 · Cited by 48

Relationship of state educational criteria and demographic variables to school-system prevalence of mental retardation.

Patrick, J. L., & Reschly, D. J. (1982) · PubMed · Cited by 47

The heterocellular heart: identities, interactions, and implications for cardiology

Lother, A., & Kohl, P. K. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-023-01000-6 · Cited by 46

Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases

Li, Y., Chen, J., Bolinger, A. A., Chen, H., Liu, Z., Cong, Y., Brasier, A. R., Pinchuk, I. V., Tian, B., & Zhou, J. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab190 · Cited by 45

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment

Gorica, E., Geiger, M. A., Venanzio, L. D., Atzemian, N., Kleeberger, J., Grigorian, D., Mongelli, A., Veseli, B. E., Mohammed, S. A., Ruschitzka, F. T., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02774-w · Cited by 50

The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy

Li, Z., Guo, Z., Lan, R., Cai, S., Lin, Z., Li, J., Wang, J., Li, Z., & Liu, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.012 · Cited by 43

BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy

Antolic, A., Wakimoto, H., Jiao, Z., Gorham, J. M., DePalma, S. R., Lemieux, M. E., Conner, D. A., Lee, D. Y., Qi, J., Seidman, J. G., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138687 · Cited by 41

Roles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis

Shao, J., Liu, J., & Zuo, S. (2022) · Cells · doi:10.3390/cells11152347 · Cited by 41

Fibulin7 Mediated Pathological Cardiac Remodeling through EGFR Binding and EGFR‐Dependent FAK/AKT Signaling Activation

Zheng, X., Liu, L., Liu, J., Zhang, C., Zhang, J., Qi, Y., Xie, L., Zhang, C., Yao, G., & Bu, P. (2023) · Advanced Science · doi:10.1002/advs.202207631 · Cited by 40

Mechanisms of Myocardial Reverse Remodelling and Its Clinical Significance: A Scientific Statement of the ESC Working Group on Myocardial Function

Falcão‐Pires, I., Ferreira, A. F., Trindade, F., Bertrand, L., Ciccarelli, M., Visco, V., Dawson, D. K., Hamdani, N., Laake, L. W. V., Lezoualc’h, F., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3264 · Cited by 47

The Long Noncoding RNA Hotair Regulates Oxidative Stress and Cardiac Myocyte Apoptosis during Ischemia-Reperfusion Injury

Meng, K., Jiao, J., Zhu, R., Wang, B.-Y., Mao, X., Zhong, Y., Zhu, Z., Yu, K., Ding, Y. P., Xu, W., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1645249 · Cited by 40

The therapeutic potential of BRD4 in cardiovascular disease

Lin, S., & Du, L. (2020) · Hypertension Research · doi:10.1038/s41440-020-0459-4 · Cited by 40

BRD4 inhibitor JQ1 inhibits and reverses mechanical injury-induced corneal scarring

Qu, M., Zhang, X., Hu, X., Dong, M., Pan, X., Bian, J., & Zhou, Q. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0066-1 · Cited by 39

Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis

He, Z., Jiao, H., An, Q., Zhang, X., Dan, Z., Xu, J., Liu, H., Ma, L., & Zhao, W. H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.018 · Cited by 42

Epi-Drugs in Heart Failure

Gorica, E., Mohammed, S. A., Ambrosini, S., Calderone, V., Costantino, S., & Paneni, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.923014 · Cited by 39

Estrogen signaling as a bridge between the nucleus and mitochondria in cardiovascular diseases

Guajardo-Correa, E., Silva-Agüero, J. F., Calle, X., Chiong, M., Henríquez, M., García‐Rivas, G., Latorre, M., & Parra, V. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.968373 · Cited by 41

Inhibition of BRD 4 attenuates cardiomyocyte apoptosis via NF ‐κB pathway in a rat model of myocardial infarction

Sun, Y., Xie, Y., Du, L., Sun, J., & Liu, Z. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12320 · Cited by 38

Structure-Based Discovery and Optimization of Furo[3,2- c ]pyridin-4(5 H )-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors

Li, J., Zhang, C., Xu, H., Wang, C., Dong, R., Shen, H., Zhuang, X., Chen, X., Li, Q., Lu, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00100 · Cited by 36

The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy

Dabravolski, S. A., Sadykhov, N. K., Kartuesov, A. G., Borisov, E. E., Sukhorukov, V. N., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147863 · Cited by 36

Unlocking the secrets of aging: Epigenetic reader BRD4 as the target to combatting aging-related diseases

Sun, J., Gui, Y., Zhou, S., & Zheng, X. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.11.006 · Cited by 38

BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity

Khoueiry, P., Gahlawat, A. W., Petretich, M., Michon, A., Simola, D. F., Lam, E. Y. N., Furlong, E. E. M., Beneš, V., Dawson, M. A., Prinjha, R. K., et al. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0286-5 · Cited by 34

Transcription Factor GATA4 Regulates Cell Type–Specific Splicing Through Direct Interaction With RNA in Human Induced Pluripotent Stem Cell–Derived Cardiac Progenitors

Zhu, L., Choudhary, K., González‐Terán, B., Ang, Y.-S., Thomas, R., Stone, N. R., Liu, L., Zhou, P., Zhu, C., Ruan, H., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057620 · Cited by 31

BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment

Andrieu, G. P., Shafran, J. S., Deeney, J. T., Bharadwaj, K. R., Rangarajan, A., & Denis, G. V. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0917-380rr · Cited by 33

Effective Modulation of Inflammation and Oxidative Stress for Enhanced Regeneration of Intervertebral Discs Using 3D Porous Hybrid Protein Nanoscaffold

Yang, L., Bhujel, B., Hou, Y., Luo, J., An, S. B., Han, I., & Lee, K. (2023) · Advanced Materials · doi:10.1002/adma.202303021 · Cited by 31

Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential

Meddens, C., van der List, A. C. J., Nieuwenhuis, E. E. S., & Mokrý, M. (2019) · Gut · doi:10.1136/gutjnl-2018-317516 · Cited by 31

The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats

Piquereau, J., Boët, A., Péchoux, C., Antigny, F., Lambert, M., Gressette, M., Ranchoux, B., Gambaryan, N., Domergue, V., Mumby, S. E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071527 · Cited by 29

Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins

Fu, Y., Zhang, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113853 · Cited by 29

Prevention of Fibrosis and Pathological Cardiac Remodeling by Salinomycin

Burke, R. M., Dirkx, R. A., Quijada, P. J., Lighthouse, J. K., Mohan, A. M., O’Brien, M., Wojciechowski, W., Woeller, C. F., Phipps, R. P., Alexis, J. D., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317791 · Cited by 28

Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics

Ma, Z., Bolinger, A. A., Zhou, J., & Tian, B. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2175317 · Cited by 27

Etiology of super-enhancer reprogramming and activation in cancer

Zhou, R. W., & Parsons, R. E. (2023) · Epigenetics & Chromatin · doi:10.1186/s13072-023-00502-w · Cited by 31

Epigenetic therapies in heart failure

Alexanian, M., Padmanabhan, A., McKinsey, T. A., & Haldar, S. M. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.04.012 · Cited by 26

The Role of Cardiac Fibroblast Heterogeneity in Myocardial Fibrosis and Its Novel Therapeutic Potential

Chimenti, I., Pagano, F., Cozzolino, C., Icolaro, F., Floris, E., & Picchio, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125882 · Cited by 25

BET-inhibition by JQ1 alleviates streptozotocin-induced diabetic cardiomyopathy

Guo, M., Wang, H., & Chen, W. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.018 · Cited by 26

BRD4 inhibition slows HF progression

Ummarino, D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.86 · Cited by 11

BET inhibitor attenuates heart failure

Cully, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.125 · Cited by 12

BET Protein-Mediated Transcriptional Regulation in Heart Failure

Ijaz, T., & Burke, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116059 · Cited by 15

BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy

Antolic, A., Wakimoto, H., Jiao, Z., Gorham, J. M., DePalma, S. R., Lemieux, M. E., Conner, D. A., Lee, D. Y., Qi, J., Seidman, J. G., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138687 · Cited by 41

From Chromatin Readers to Heart Failure: BET Protein Family Members in Cardiac Remodeling

Lbik, D. (2019) · doi:10.53846/goediss-7453 · Cited by 1